Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL1-C52H8 | Cynomolgus | Cynomolgus IL-13 R alpha 1 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
IL1-H82E8 | Human | Biotinylated Human IL-13 R alpha 1 Protein, His,Avitag™ (MALS & SPR verified) | ![]() |
![]() ![]() |
![]() ![]() |
IL1-H82F6 | Human | Biotinylated Human IL-13 R alpha 1 Protein, Fc,Avitag™ (SPR verified) | ![]() |
![]() ![]() |
![]() ![]() |
IL1-M52H7 | Mouse | Mouse IL-13 R alpha 1 Protein, His Tag | ![]() |
![]() ![]() |
|
IL1-M5258 | Mouse | Mouse IL-13 R alpha 1 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
IL1-H5224 | Human | Human IL-13 R alpha 1 Protein, His Tag (MALS & SPR verified) | ![]() |
![]() ![]() |
![]() ![]() |
Biotinylated Human IL-13 R alpha 1 Protein, His,Avitag (Cat. No. IL1-H82E8) captured on Biotin CAP-Series S Sensor Chip can bind Human IL-13, His Tag (Cat. No. IL3-H52H4) with an affinity constant of 34.4 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | Details |
Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | Details |
This web search service is supported by Google Inc.